Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Clinical evidence

COMP005

74 evidence topics · 26 sources

Objective
Location and study date
Study dates in the registry record
MilestoneRegistry entry
Study start (actual)“2023-01-24”
Primary completion (actual)“2025-05-28”
Study completion (actual)“2026-04-15”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics
CharacteristicCOMP360 25 mg (N=171)Placebo (N=87)
Female, n (%)“93 (54.4)”“47 (54.0)”
White, n (%)“149 (87.1)”“78 (89.7)”
Asian, n (%)“11 (6.4)”“4 (4.6)”
Black or African American, n (%)“6 (3.5)”“2 (2.3)”
American Indian or Alaska Native, n (%)“0”“1 (1.1)”
Other race, n (%)“5 (2.9)”“2 (2.3)”
Age, years, mean (SD)“45.9 (13.4)”“45.3 (14.4)”
Age, years, minimum and maximum“19, 77”“22, 72”
Age ≥65 years, n (%)“15 (8.8)”“11 (12.6)”
Prior psilocybin experience, n (%)“5 (2.9)”“5 (5.7)”
Prior psychedelic experience including psilocybin, n (%)“8 (4.7)”“6 (6.9)”
BMI, kg/m2, mean (SD)“28.4 (6.2)”“27.7 (6.1)”
Treatment history and baseline MADRS
CharacteristicCOMP360 25 mg (N=171)Placebo (N=87)
Failed treatments in current episode: 1, n (%)“2 (1.2)”“1 (1.1)”
Failed treatments in current episode: 2, n (%)“114 (66.7)”“62 (71.3)”
Failed treatments in current episode: 3, n (%)“45 (26.3)”“19 (21.8)”
Failed treatments in current episode: 4, n (%)“10 (5.8)”“4 (4.6)”
Failed treatments in current episode: 5, n (%)“0”“1 (1.1)”
Treatments withdrawn in screening: 0, n (%)“58 (33.9)”“26 (29.9)”
Treatments withdrawn in screening: 1, n (%)“38 (22.2)”“32 (36.8)”
Treatments withdrawn in screening: 2, n (%)“50 (29.2)”“21 (24.1)”
Treatments withdrawn in screening: more than 2, n (%)“25 (14.6)”“8 (9.2)”
MADRS total score at baseline, mean (SD)“31.5 (5.5)”“31.5 (5.9)”
Mild (11-19), n (%)“1 (0.6)”“2 (2.3)”
Moderate (20-30), n (%)“73 (42.7)”“33 (37.9)”
Severe (≥31), n (%)“97 (56.7)”“52 (59.8)”
Depression diagnosis history
CharacteristicCOMP360 25 mg (N=171)Placebo (N=87)
Length of current episode, months, mean (SD)“34.1 (29.1)”“38.6 (33.0)”
Current episode less than 1 year, n (%)“30 (17.5)”“20 (23.0)”
Current episode 1-2 years, n (%)“52 (30.4)”“19 (21.8)”
Current episode more than 2 years, n (%)“89 (52.0)”“48 (55.2)”
Lifetime depressive episodes, mean (SD)“7.7 (10.9)”“7.2 (7.6)”
Lifetime episodes 2-5, n (%)“107 (62.6)”“54 (62.1)”
Lifetime episodes 6-10, n (%)“40 (23.4)”“21 (24.1)”
Lifetime episodes more than 10, n (%)“23 (13.5)”“12 (13.8)”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events in Part A, through Week 6
EventCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TEAE up to Week 6“120 (70.2)”“34 (39.1)”
Any serious TEAE up to Week 6“4 (2.3)”“1 (1.1)”
Any TEAE with onset on day of dosing“118 (69.0)”“23 (26.4)”
Resolved within 1 day“111 (64.9)”“22 (25.3)”
Resolved after more than 1 and up to 2 days“15 (8.8)”“2 (2.3)”
Resolved after more than 2 days“22 (12.9)”“5 (5.7)”
Treatment-emergent adverse events in Part A with incidence above 5%
MedDRA preferred termCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TEAE“86 (50.3)”“12 (13.8)”
Headache“42 (24.6)”“10 (11.5)”
Nausea“35 (20.5)”“3 (3.4)”
Hallucination, visual“24 (14.0)”“0”
Anxiety“14 (8.2)”“2 (2.3)”
Dizziness“10 (5.8)”“2 (2.3)”
Illusion“9 (5.3)”“1 (1.1)”
Treatment-emergent serious adverse events in Part A
MedDRA preferred termCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any SAE“4 (2.3)”“1 (1.1)”
Suicidal ideation“2 (1.2)”“0”
Depression suicidal“1 (0.6)”“0”
Major depression“0”“1 (1.1)”
Cellulitis“1 (0.6)”“0”
Diverticulitis“1 (0.6)”“0”
Treatment-emergent adverse events through Week 26
EventCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TEAE up to Week 26“145 (84.8)”“52 (59.8)”
Any serious TEAE up to Week 26“8 (4.7)”“2 (2.3)”
Any TEAE with onset on day of dosing“121 (70.8”“25 (28.7)”
Resolved within 1 day“115 (67.3)”“24 (27.6)”
Resolved after more than 1 and up to 2 days“16 (9.4)”“2 (2.3)”
Resolved after more than 2 days“22 (12.9)”“5 (5.7)”
MedDRA preferred term (incidence above 10% in the 25 mg arm)COMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TEAE“145 (84.8)”“52 (59.8)”
Headache“61 (35.7)”“16 (18.4)”
Nausea“44 (25.7)”“5 (5.7)”
Hallucination, visual“27 (15.8)”“0”
Anxiety“22 (12.9)”“3 (3.4)”
Treatment-emergent serious adverse events through Week 26
MedDRA preferred termCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TESAE“8 (4.7)”“2 (2.3)”
Suicidal ideation“4 (2.3)”“0”
Depression suicidal“1 (0.6)”“0”
Major depression“0”“1 (1.1)”
Cellulitis“1 (0.6)”“0”
Diverticulitis“1 (0.6)”“0”
Urinary tract infection bacterial“0”“1 (1.1)”
Clavicle fracture“1 (0.6)”“0”
Rib fracture“1 (0.6)”“0”
Pneumothorax“1 (0.6)”“0”
Anaphylactic reaction“1 (0.6)”“0”
Study limitations
Summary: functional unblinding, placebo comparator, observed-case and open-label follow-up, preliminary data

COMP005 compared COMP360 25 mg with a matched placebo, and the company states that concerns about functional unblinding and expectancy bias could hinder the interpretability or regulatory acceptability of its trial data. A systematic review reports that psychedelic trials have generally not reported pre-trial expectancy or blinding success and argues that their effect sizes are likely over-estimated. No statistical analyses were performed after the Week 6 primary analysis: Part B and Part C results are observed data, the responder analysis is post hoc, and protocol-allowed antidepressants were permitted in Parts B and C. Part C was open-label and was entered by approximately 70% of participants. The results are preliminary, had not been reviewed by the FDA at the 2025 topline announcement, and are reported in company documents and congress abstracts.

Blinding and expectancy confounds in psychedelic trials